-
Mashup Score: 38Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders - 12 month(s) ago
Background Recent trials suggest that programmed cell death 1 (PD-1)-directed immunotherapy may be beneficial for some patients with anal squamous cell carcinoma and biomarkers predictive of response are greatly needed. Methods This multicenter phase II clinical trial ([NCT02919969][1]) enrolled patients with metastatic or locally advanced incurable anal squamous cell carcinoma (n=32). Patients received pembrolizumab 200 mg every 3 weeks. The primary endpoint of the trial was objective response rate (ORR). Exploratory objectives included analysis of potential predictive biomarkers including assessment of tumor-associated immune cell populations with multichannel immunofluorescence and analysis of circulating tumor tissue modified viral-human papillomavirus DNA (TTMV-HPV DNA) using serially collected blood samples. To characterize the clinical features of long-term responders, we combined data from our prospective trial with a retrospective cohort of patients with anal cancer treated wi
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13Cabozantinib Efficacy Prompts CABINET Trial Unblinding in Advanced Pancreatic and Extra-Pancreatic NETs - 1 year(s) ago
Interim data from the phase 3 CABINET trial demonstrated significant improvement in progression-free survival with cabozantinib vs placebo in patients with advanced pancreatic or extra-pancreatic neuroendocrine tumors following progression on prior systemic therapy.
Source: www.onclive.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Thrilled to hear today’s announcement that the CABINET trial is positive with cabozantinib having efficacy in Pancreatic and Extra-Pancreatic #NeuroendocrineCancer Very happy for my @DanaFarber colleague Jen Chan. https://t.co/dQdtpW3gNx
-
-
Mashup Score: 2
Author links open overlay panel Esther Baranov MD, Jonathan A. Nowak MD, PhD Colorectal carcinoma (CRC) is the third most-commonly diagnosed cancer worldwide and the second largest contributor to cancer-related death. 1, 2 In addition, the incidence in individuals younger than 50 years of age (early-onset CRC) has increased steadily in recent years. 2 Since the original description of CRC pathogenesis as a stepwise series of linked molecular and morphologic events over 30 years ago, the burgeoning field
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet-
RT @jonathan_nowak: Free online from #surgpathclinics for a limited time: https://t.co/S6bZ63pqF9 Exciting to see how KRAS inhibition an…
-
-
Mashup Score: 0Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer - 3 year(s) ago
Purpose: Activating missense mutations of KRAS are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly heterogeneous, and data on the potential isoform-dependent therapeutic vulnerabilities are still lacking. Experimental design: We developed an isogenic cell-based platform to compare the oncogenic properties and specific therapeutic…
Source: Clinical Cancer ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Insightful paper from @DrMarkAwad, Pasi Janne, and Chiara Ambrogio analyzing functional and genomic differences in #NSCLC tumors harboring different #KRAS mutant isoforms. https://t.co/VmuqiM66Oj
-
-
Mashup Score: 0
The stunning Covid vaccines manufactured by Pfizer-BioNTech and Moderna drew upon long-buried discoveries made in the hopes of ending past epidemics.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Beautifully written article describing the decades of scientific advances that led to the development of the mRNA #COVID vaccines. https://t.co/AlRyQFQJ24
-
-
Mashup Score: 7Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics - 3 year(s) ago
Among patients with multiple primary cancers, the prevalence of germline pathogenic variants (PVs) in actionable cancer genes increases with the number of primary cancers (PCs): 13.1% with 2 PCs, 15….
Source: American Cancer Society JournalsCategories: Hem/Oncs, Latest HeadlinesTweet-
Data from this paper really drives home the point that patients w/ multiple cancers are a unique population. Pathogenic germline mutations were found in 13% of pts w/ 2 cancers and 18% of pts w/ 4 cancers. Germline screening is clearly needed in these pts. https://t.co/dN1o36qsla https://t.co/IStIX8NkGX
-
-
Mashup Score: 1Clinical Research Job: Regulatory Coordinator II - GI Oncology at Dana-Farber Cancer Institute in 450 Brookline Ave, Boston, MA - 3 year(s) ago
Regulatory Coordinator II – GI Oncology job
Source: careers.dana-farber.orgCategories: Latest Headlines, Oncologists2Tweet-
Looking for senior and junior regulatory specialists to join our DFCI GI Oncology group and help with our expanding number of investigator-initiated clinical trials. Candidates with experience as a CRC or as a regulatory specialist are encouraged to apply. https://t.co/dseYhk9xgB
-
-
Mashup Score: 8
The findings demonstrate the feasibility of rapid identification of the biologic relevance of somatic mutations, which thus advances clinicians’ ability to make informed treatment decisions.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
@MPishvaian There is a very report of a cholangio pt with an FGFR2 F276C extracellular domain mutation who responded to infigratinib. Whenever I see a mutated cysteine in the extracellular domain, I get suspicious that it will predict FGFRi sensitivity. @MiteshBorad https://t.co/rdeQhBzBhx
-
-
Mashup Score: 8TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma - 4 year(s) ago
ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic cholangiocarcinoma (ICC) harboring activating FGFR2 gene fusions. Unfortunately, acquired resistance develops and is often associated with the emergence of secondary FGFR2 kinase domain mutations. Here, we report that the irreversible…
Source: Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
Lipika Goyal and Nabeel Bardeesy demonstrated that the irreversible FGFR2 inhibitor futibatinib (TAS-120) can overcome acquired resistance caused by reversible FGFR inhibitors like pemigatinib and infigratinib. https://t.co/xccwuDF5Kg #TumorBoardTuesday (23/n) https://t.co/7N3H33HPdw
-
-
Mashup Score: 2
We conducted next generation DNA sequencing on 335 biliary tract cancers and characterized the genomic landscape by anatomic site within the biliary tree. In addition to frequent FGFR2 fusions among patients with intrahepatic cholangiocarcinoma (IHCC), we identified FGFR2 extracellular domain in-frame deletions (EIDs) in 5 of 178 (2.8%) patients with IHCC, including two patients with FGFR2…
Source: Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
We observed several patients with FGFR2 extracellular domain in-frame deletions (INDELs) who had substantial responses to FGFR inhibitors. We see FGFR2 INDELs in about 2%-3% of intrahepatic cholangiocarcinoma patients. https://t.co/H2C56AMx7I #TumorBoardTuesday (15/n)
-
In our new paper, @BHuffmanMD did a wonderful job examining #PD1 immunotherapy in advanced #AnalCancer. Despite being an #HPV driven cancer, with persistent viral antigen production, there is a wide range of responses to anti-PD1 immunotherapy. https://t.co/OAoPTBZNU0